Bristol-Myers Squibb reported the CFDA approved its direct-acting, all oral, interferon-free hepatitis C regimen. The approval follows a Phase III trial that showed Daklinza (daclatasvir) and Sunvepra (asunaprevir) successfully cleared HCV in 91% of patients with type 1b HCV genotype after 24 weeks of treatment. It is the first non-interferon treatment approved in China. In addition, Daklinza was approved in combination with other agents for adults with HCV genotypes 1-6.
